Solventum Announces Planned Retirement of Chief Accounting Officer
TipRanks (Tue, 24-Mar 5:02 PM ET)
Solventum to Participate in the 2026 KeyBanc Healthcare Forum
PRNewswire (Wed, 11-Mar 4:05 PM ET)
Middleby Appoints Glenn Eisenberg To Board of Directors
Business Wire (Fri, 6-Mar 7:00 AM ET)
Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance
PRNewswire (Thu, 26-Feb 4:05 PM ET)
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
Solventum trades on the NYSE stock market under the symbol SOLV.
As of March 26, 2026, SOLV stock price climbed to $65.09 with 60,887 million shares trading.
SOLV has a beta of 0.90, meaning it tends to be less sensitive to market movements. SOLV has a correlation of 0.28 to the broad based SPY ETF.
SOLV has a market cap of $11.29 billion. This is considered a Large Cap stock.
Last quarter Solventum reported $2 billion in Revenue and $1.57 earnings per share. This beat revenue expectation by $36 million and exceeded earnings estimates by $.07.
The top ETF exchange traded funds that SOLV belongs to (by Net Assets): VTI, VOO, VB, RSP, VBR.
SOLV has underperformed the market in the last year with a price return of -13.1% while the SPY ETF gained +14.9%. SOLV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.8% and -3.7%, respectively, while the SPY returned -5.0% and -3.0%, respectively.
SOLV support price is $63.40 and resistance is $65.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SOLV shares will trade within this expected range on the day.
